Skip to main content
. 2020 Sep 28;11(11):3317–3325. doi: 10.1111/1759-7714.13675

Table 3.

Characteristics of patients receiving immune checkpoint inhibitors (n = 4)

Patient Age Histology ICIs FVC, L FVC, % predicted DLCO, mL/min/mmHg DLCO, % predicted GAP stage mGAP stage
1 61 SCC Pembrolizumab 2.75 71.8 11.27 61.0 I I
2 78 SCC Pembrolizumab 2.40 81.1 10.91 87.8 I I
3 69 NSCLC Pembrolizumab 1.96 84.8 8.29 53.9 I I
4 73 NSCLC Nivolumab 4.30 118.5 16.76 99.9 I I

DLCO, carbon monoxide diffusing capacity; FVC, forced vital capacity; GAP, gender, age, and physiology; ICIs, immune checkpoint inhibitors; mGAP, modified GAP; NSCLC, non‐small cell carcinoma; SCC, squamous cell carcinoma.